Company: DMAC
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001437749-25-008018
Chunk: 2

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 8
Chunk 2
---
Financial Statements

Our consolidated financial statements are included in “ Part II, Item 8. Financial Statements and Supplementary Data. ”

Financial Statement Schedules

All financial statement schedules are omitted because they are inapplicable since we are a smaller reporting company.

Exhibits

The exhibits being filed or furnished with this report are listed below, along with an indication as to each management contract or compensatory plan or arrangement.

A copy of any of the exhibits listed or referred to herein will be furnished at a reasonable cost to any person who is a shareholder upon receipt from any such person of a written request for any such exhibit. Such request should be sent to: Mr. Scott Kellen, Chief Financial Officer and Corporate Secretary, DiaMedica Therapeutics Inc., 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, Attn: Shareholder Information.

  Item No.      Item                                                                                                                                 Method of Filing                                                                                                                                                    
       3.1      Notice of Articles of DiaMedica Therapeutics Inc. dated June 16, 2023                                                                Incorporated by reference to Exhibit 3.1 to DiaMedica’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024                             
                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                     (File No. 001-36291)                                                                                                                                                
       4.1      Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934                                   Incorporated by reference to Exhibit 4.1 to DiaMedica’s Annual Report on Form 10-K for the year ended December 31, 2023                                             
                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                     (File No. 001-36291)                                                                                                                                                
       4.2      Specimen Certificate representing Voting Common Shares of DiaMedica Therapeutics Inc.                                                Incorporated by reference to Exhibit 4.2 to DiaMedica’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 4, 2019             
                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                     (File No. 001-36291)                                                                                                                                                
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
       3.2      Amended and Restated Articles of DiaMedica Therapeutics Inc. Effective May 17, 2023                                                  Incorporated by reference to Exhibit 3.1 to DiaMedica’s Current Report on Form 8